Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment

2018 ◽  
Vol 66 (5) ◽  
pp. 605-610 ◽  
Author(s):  
Ana Beatriz da Silva Sacerdote ◽  
Norma Arteiro Filgueira ◽  
Silvana de Barros Barreto ◽  
Andréa Dória Batista ◽  
Edmundo Pessoa Lopes
2019 ◽  
Vol 70 (1) ◽  
pp. e202-e203
Author(s):  
Cristina Stasi ◽  
Sinan Sadalla ◽  
Eleonora Carradori ◽  
Monica Monti ◽  
Luisa Petraccia ◽  
...  

Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 442-442 ◽  
Author(s):  
J GALERAS ◽  
I CIRERA ◽  
S COLL ◽  
C MARQUEZ ◽  
M GIMENEZ ◽  
...  

2017 ◽  
Vol 55 (09) ◽  
pp. 848-856 ◽  
Author(s):  
Bernhard Schlevogt ◽  
Katja Deterding ◽  
Kerstin Port ◽  
Christoph Siederdissen ◽  
Lisa Sollik ◽  
...  

Abstract Background and aim The advent of direct-acting antivirals has revolutionized treatment of chronic hepatitis C with very high cure rates and excellent tolerability compared to interferon-based hepatitis C virus (HCV) treatment. However, long-term effects of interferon-free cure of HCV infection on the metabolic condition of patients have not been investigated so far. Methods We investigated weight development during and after antiviral treatment of hepatitis C. In a prospective single-center cohort study, interferon-free antiviral treatment was initiated in 284 patients. Each patient’s weight was monitored 1 year before the start of treatment, at baseline (BL), end of treatment (EOT), follow-up week 24 (FU24), and follow-up week 48 (FU48). Results Weight gain after HCV cure was observed in 20 %, 33 %, and 44 % of patients at EOT, FU24, and FU48, respectively. The mean overall weight change at FU48 compared to baseline was 1.45 kg (95 % CI 0.44; 2.46, p = 0.02, compared to the pretreatment period). Multivariate regression revealed age as the only factor predicting weight change at FU48 (B − 0.107, 95 % CI, − 0.202 to − 0.011, p = 0.03), while gender, cirrhosis, diabetes mellitus, ribavirin, and body mass index had no influence. In the subgroup of patients younger than 60 years, mean weight gain at FU48 compared to baseline was 2.8 kg (95 % CI, 1.23 – 4.4). In contrast, patients 60 years and older had a mean weight change of − 0.04 kg (95 % CI, − 1.12 to 1.03, p = 0.005). Conclusions Cure of HCV by interferon-free antiviral treatment was associated with weight gain in up to 44 % of patients during long-term follow-up. Weight gain occurred predominantly in patients younger than 60 years. The precise mechanism of weight gain remains to be elucidated.


2014 ◽  
Vol 95 (6) ◽  
pp. 924-928
Author(s):  
G Z Aripkhodzhaeva

Aim. To investigate the relation of prooxidant and antioxidant systems with adverse effects of antiviral alpha interferon treatment in chronic hepatitis C. Methods. The study included 67 patients with chronic hepatitis C aged 19 to 45 years [males - 28 (41.8%), females - 39 (58.2%)] who were receiving antiviral treatment. Prooxidant (diene ketones and diene conjugates, malon dialdehyde) and antioxidant (catalase, superoxide dismutase, glutathione and glutathione-dependent enzymes) systems indicators were measured. According to the severity of side effects, patients were distributed to two groups. The first group consisted of 19 (28.4%) patients with transient passing adverse effects, usually manifesting as short-term flu-like syndrome after the medication injection, lasting no longer than 2-3 weeks of treatment. The second group consisted of 48 patients (71.6%) with prolonged side effects, registered throughout the whole treatment period. Results: Flu-like syndrome with intense myalgia and asthenic syndrome were the most frequent side effects (89.5 and 83.3% of cases, respectively). Dyspepsia, psychopathy and arthralgia were less common (79.2, 72.9 and 68.7%, respectively). Over than a half of the patients lost weight (7-9 kg compared to baseline weight), and also had alopecia and autoimmune thyroiditis. Most of the patients could not tolerate the treatment, 33 (49.2%) patients aborted the treatment. In patients with long-term side effects, low baseline levels of glutathione reductase, glutathione peroxidase, glutathione transferase were revealed (p 0.05). Patients with long-term side effects of antiviral treatment preserved high levels (p 0.05) of diene ketones and diene conjugates and statistically significant (p 0.05) suppression of antioxidant system at the 10-12 weeks of treatment. Conclusion. Examined patients with chronic hepatitis C had diverse activity of antioxidant system. Long-term side effects were seen in patients with low levels of parameters of antioxidant protection at the baseline.


2001 ◽  
Vol 120 (5) ◽  
pp. A380-A380
Author(s):  
P PONSODAJR ◽  
P BLANCSR ◽  
G PHILIPPEPAGEAUXSR ◽  
J RAMOSSR ◽  
J DUCOSSR ◽  
...  

2011 ◽  
Vol 152 (22) ◽  
pp. 876-881
Author(s):  
Alajos Pár

The review discusses the genetic polymorphisms involved in the pathogenesis of hepatitis C virus (HCV) infection, that may determine the outcome of disease. In this field earlier both certain major histocompatibility complex (MHC) alleles and some cytokine gene variants have also been studied. Recently, the genome-wide association study (GWAS) and targeted single nucleotide polymorphism (SNP) analysis have revealed that a variant in the promoter region of interleukin-28B (IL-28B) gene is strongly linked to viral clearance and it may be the strongest pretreatment predictor of treatment response in chronic hepatitis C. Last year it was shown that two genetic variants leading to inosine triphosphatase deficiency protect against haemolytic anemia in patients receiving ribavirin during antiviral treatment for chronic HCV infection. Orv. Hetil., 2011, 152, 876–881.


Sign in / Sign up

Export Citation Format

Share Document